| Company Name: |
Nanjing Chemlin Chemical Co., Ltd
|
| Tel: |
025-83697070 13770331960 |
| Email: |
info@chemlin.com.cn |
| Products Intro: |
Product Name:Macimorelin acetate; 2-Amino-N-((R)-1-(((R)-1-formamido-2-(1H-indol-3-yl)ethyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-2-methylpropanamide acetate
CAS:945212-59-9
|
MaciMorelin Acetate manufacturers
|
| | MaciMorelin Acetate Basic information |
| Product Name: | MaciMorelin Acetate | | Synonyms: | MaciMorelin Acetate;AEZS-130 acetate|||AEZS-130 acetate|||EP-1572 acetate;EP-1572 acetate;2-Amino-N-((R)-1-(((R)-1-formamido-2-(1H-indol-3-yl)ethyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-2-methylpropanamide acetate | | CAS: | 945212-59-9 | | MF: | C28H34N6O5 | | MW: | 534.60676 | | EINECS: | | | Product Categories: | | | Mol File: | 945212-59-9.mol |  |
| | MaciMorelin Acetate Chemical Properties |
| storage temp. | -10 to -25°C | | solubility | DMSO: 2mg/mL, clear | | form | Solid | | color | White to off-white | | InChIKey | UJVDJAPJQWZRFR-DHIUTWEWSA-N | | SMILES | [nH]1c2c(c(c1)C[C@@H](NC(=O)[C@H](NC(=O)C(N)(C)C)Cc3c4c([nH]c3)cccc4)NC=O)cccc2 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | MaciMorelin Acetate Usage And Synthesis |
| Uses | Macimorelin (EP-1572) acetate, a GH secretagogue, is an orally active GHSR agonist. Macimorelin acetate stimulates GH release. Macimorelin acetate can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS)[1][2][3]. | | Biological Activity | Macimorelin (AEZS-130; ARD-07; EP1572; UMV1843; Aib-DTrp-DgTrp-CHO) is an orally active peptido-mimetic growth hormone (GH) secretagogue (GHS) th at targets human and animal GHS-receptor (IC50 in nM = 10.2/ghrelin, 12.3/hexaghrelin, 15.6/macimorelin against ghrelin binding to human GHS-R) with potent and selective GH-releasing activity in vivo (GH level = 158.8 μg/L 15 min post 300 μg/kg s.c. in neonatal rats; 11.3 μg/L without treatment). | | in vivo | Macimorelin (5 mg/kg, i.p. twice daily for 2 weeks) acetate decreased the number and duration of seizures in IHKA mouse model[2].
| Animal Model: | Intrahippocampal kainic acid (IHKA) mouse model[2] | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneal injection (i.p.), twice daily for 2 weeks. | | Result: | Significantly decreased the number and duration of seizures during the treatment period, but had no antiepileptogenic or disease-modifying effect. |
| | References | [1] Jose M Garcia, et al. Macimorelin as a Diagnostic Test for Adult GH Deficiency. J Clin Endocrinol Metab. 2018 Aug 1;103(8):3083-3093. DOI:10.1210/jc.2018-00665
[2] An Buckinx, et al. Translational potential of the ghrelin receptor agonist macimorelin for seizure suppression in pharmacoresistant epilepsy. Eur J Neurol. 2021 Sep;28(9):3100-3112. DOI:10.1111/ene.14992
[3] Ali SA, Garcia JM. Randomized clinical trial of the novel oral ghrelin mimetic macimorelin in the treatment of cancer cachexia: study design and preliminary results. Endocr Rev. 2013;34: |
| | MaciMorelin Acetate Preparation Products And Raw materials |
|